An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

In case you missed it: catch up with snippets from interviews published by In Vivo this week. 

The European MedTech Forum’s CEO panel set out to address high-level global, long-range issues, but from the start it got log jammed in regulatory issues. Not in the script perhaps, but wholly understandable, as new EU regulations will have huge strategic importance for how companies do business – and in the case of start-ups, if they can continue to do business.

In a world where national economies are beset by conflicting spending priorities, health care is oftentimes too low on the agenda, health care observers say. One of these is Boston Scientific senior vice-president Eric Thépaut, who understands the dilemmas, but says that health care will soon force its way up the priority list. He has advice for future-ready medtech innovators.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Ten years after our first encounter with MIT’s Robert Langer, In Vivo sits down with the polymath professor – arguably the most inventive and prolific life scientist of his generation – to identify key challenges in medicine.